Liposomal doxorubicin: all 237 studies that test it
Page 1 of 3. Open to participants first (21), then studies with results posted, then the rest; newest registration first within each.
- Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast CancerRecruitingNCT07635342Phase 2
- Phase II Study of Ultrasound and ctDNA Guided Neoadjuvant Systemic Therapy for Patients With HER2-positive Early Breast Cancer (UC HER Trial)Not yet recruitingNCT07565324Phase 2
- Metastatic Ewing's Trial Testing Schedule Enhancement to Improve OutcomesRecruitingNCT07194044Phase 1
- Pegylated Liposomal Doxorubicin (PLD) Versus Active Surveillance for Advanced Soft Tissue Sarcoma Patients Who Had Controlled Disease After Standard Anthracycline-based Treatment (MELODY)RecruitingNCT06981637Phase 2
- IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)RecruitingNCT06849986Phase 2
- Pegylated Liposomal Doxorubicin Plus Adebrelimab With or Without Mirabegron in Relapsed Ovarian CancerRecruitingNCT06791460Phase 2/3
- First-line Treatment of Advanced/unresectable DDLPSNot yet recruitingNCT06694324Phase 2
- APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced STRecruitingNCT06687070Phase 1
- Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast CancerRecruitingNCT06434064Phase 2
- The Combination of Radiotherapy, Chemotherapy and Immunotherapy in High-Risk Localized Soft Tissue SarcomaRecruitingNCT05774275Phase 1/2
- Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast CancerRecruitingNCT05748834Phase 2
- Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced SarcomaRecruitingNCT05711615Phase 1
- To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical StudyRecruitingNCT05656079Not applicable
- Combination Therapy for Recurrent Ovarian CancerRecruitingNCT05610735Phase 1/2
- The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)RecruitingNCT05536102Phase 2
- Doxorubicin Hydrochloride Liposome Combined With Irinotecan (AI Regimen) Versus VIT Regimen in the Treatment of Relapsed and Refractory Pediatric Rhabdomyosarcoma: a Prospective, Open-label, Randomized Controlled, Multicenter, Phase II Clinical StudyRecruitingNCT05457829Phase 2
- Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi SarcomaNot yet recruitingNCT05411237Phase 3
- Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory SarcomasRecruitingNCT05210374Phase 1
- Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast CancerRecruitingNCT05159193Phase 3
- Combination Therapy of Anthracyclines for Children With NephroblastomaNot yet recruitingNCT03892330Phase 4
- Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)RecruitingNCT01419561Phase 2
- A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT05613088Phase 2Results posted
- Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian CancersCompletedNCT05483933Phase 1Results posted
- Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian CancerTerminatedNCT05261490Phase 1/2Results posted
- Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian CancerCompletedNCT03480750Phase 1/2Results posted
- p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246CompletedNCT03268382Phase 2Results posted
- Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal CancerCompletedNCT02865811Phase 2Results posted
- A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube CancerCompletedNCT02631876Phase 3Results posted
- Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT02606305Phase 1/2Results posted
- A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200)CompletedNCT02580058Phase 3Results posted
- Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot InitiativeCompletedNCT02456857Phase 2Results posted
- Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast CancerActive, not recruitingNCT02315196Phase 2Results posted
- Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT02312245Phase 2Results posted
- Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple MyelomaCompletedNCT02186834Phase 1/2Results posted
- Correlate BRCA1 Protein Expression With Response to DNA Damaging ChemotherapyTerminatedNCT01990352Phase 2Results posted
- A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based ChemotherapyTerminatedNCT01840943Phase 3Results posted
- Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous LeukemiaCompletedNCT01736943Phase 2Results posted
- Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer(mCRC)TerminatedNCT01464593Phase 2Results posted
- Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid TumorsCompletedNCT01214668Phase 1Results posted
- Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell TransplantTerminatedNCT01078441Phase 2Results posted
- Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal AdenocarcinomaTerminatedNCT01035658Phase 1/2Results posted
- Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple MyelomaTerminatedNCT00985907Phase 1/2Results posted
- Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent SarcomaCompletedNCT00949325Phase 1/2Results posted
- Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA)CompletedNCT00945139Phase 2Results posted
- Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s SarcomaCompletedNCT00923936Phase 2Results posted
- A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian CancerCompletedNCT00913835Phase 2Results posted
- Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerTerminatedNCT00903630Phase 1/2Results posted
- Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple MyelomaTerminatedNCT00849251Phase 1/2Results posted
- Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid MalignanciesTerminatedNCT00837200Phase 2Results posted
- Safety Study of CAELYX in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines (Study P04057)(TERMINATED)TerminatedNCT00779285Phase 4Results posted
- Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM)CompletedNCT00750815Phase 1/2Results posted
- A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED)CompletedNCT00727961Phase 4Results posted
- Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple MyelomaCompletedNCT00724568Phase 1/2Results posted
- Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or TopotecanTerminatedNCT00720096Not applicableResults posted
- Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Participants With HER2-Positive Breast CancerCompletedNCT00712881Phase 2Results posted
- A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal CancersCompletedNCT00698451Phase 2Results posted
- A Study to Determine the Activity of Caelyx With Trastuzumab and Docetaxel in the Treatment of Metastatic Breast Cancer (Study P03679)CompletedNCT00687440Phase 2Results posted
- Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary AdenocarcinomaTerminatedNCT00653328Phase 2Results posted
- Therapy for Locally Advanced Breast Cancer Using Doxil, Paclitaxel, and Cyclophosphamide With AvastinCompletedNCT00635050Phase 2Results posted
- Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell CarcinomaCompletedNCT00630409Phase 2Results posted
- Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM)CompletedNCT00617591Phase 2Results posted
- Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast CancerCompletedNCT00608972Phase 2Results posted
- Pegylated Liposomal Doxorubicin (Caelyx(R)) as Monotherapy in Elderly Patients With Locally Advanced and/or Metastatic Breast Cancer (Study P05059)TerminatedNCT00604968Phase 4Results posted
- Phase II Trial to Compare the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy for HER2-positive Breast Cancer (Study P05048)CompletedNCT00550771Phase 2Results posted
- Pegylated Liposomal Doxorubicin and Docetaxel in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By SurgeryTerminatedNCT00524459Phase 2Results posted
- Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple MyelomaCompletedNCT00458705Phase 2Results posted
- Study of Taxotere and Doxil to Treat Advanced Androgen-Independent Prostate CancerCompletedNCT00456989Phase 1/2Results posted
- Doxorubicin HCL Liposome Injection (DOXIL) in Combination With Abraxane in Patients With Metastatic Breast CancerCompletedNCT00442260Phase 1/2Results posted
- Docetaxel and Liposomal Doxorubicin Chemotherapy With Enoxaparin in Patients With Advanced Pancreatic CancerTerminatedNCT00426127Phase 2Results posted
- Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple MyelomaTerminatedNCT00366106Phase 2Results posted
- Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast CancerCompletedNCT00331552Phase 1/2Results posted
- Thalidomide and Doxil® in Patients With Androgen Independent Prostate Cancer (AIPC)CompletedNCT00307294Phase 2Results posted
- Doxil & Carboplatin Plus HER2+ in Metastatic Breast CancerCompletedNCT00303108Phase 2Results posted
- Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell LymphomaCompletedNCT00290433Phase 2Results posted
- The Efficacy and Safety of Pegylated Liposomal Doxorubicin Compared With Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer (P04445/MK-2746-071)CompletedNCT00266799Phase 3Results posted
- Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast CancerCompletedNCT00258960Phase 2Results posted
- A Study Evaluating Efficacy, Toxicity, Harvest Yield and Quality of LifeCompletedNCT00222105Phase 2Results posted
- Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast CancerCompletedNCT00193037Phase 2Results posted
- Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian CancerCompletedNCT00182767Phase 1/2Results posted
- Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian CancerCompletedNCT00170573Phase 2Results posted
- Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple MyelomaCompletedNCT00148317Phase 2Results posted
- Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell LymphomaCompletedNCT00101010Phase 2Results posted
- A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple MyelomaCompletedNCT00097981Phase 3Results posted
- A Study of Docetaxel Monotherapy or DOXIL and Docetaxel in Patients With Advanced Breast CancerCompletedNCT00091442Phase 3Results posted
- S9912 Combination Chemo in Stage III Ovarian Cancer,CompletedNCT00003896Phase 2Results posted
- Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)Active, not recruitingNCT07109414Phase 2/3
- Comparing the Pharmacokinetic Profile of LY01612 and CAELYX® in Chinese Subjects With Advanced Breast CancerCompletedNCT06098599Phase 1
- Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed GlioblastomaActive, not recruitingNCT05864534Phase 2
- Doxil/Caelyx BE StudyCompletedNCT05567601Phase 1
- Sintilimab and Bevacizumab Biosimilar Combined With PLD in mTNBCStatus unknownNCT05386524Phase 2
- Study on the Correlation Between Immunoglobulin and Liposomal Doxorubicin in VivoStatus unknownNCT05354076Phase 2
- Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection (Lipodox®) in Chinese PatientsStatus unknownNCT05273944Phase 1
- Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.Active, not recruitingNCT05271318Phase 1/2
- Camrelizumab in Combination With PLD and Losartan in Patients With TNBC Who Have Received ≦ 1 Line of ChemotherapyStatus unknownNCT05097248Phase 2
- A Study to Evaluate the Combination of ATX-101 and Platinum-based ChemotherapyTerminatedNCT04814875Phase 1/2
- Pegylated Liposomal Doxorubicin Combined With Anlotinib for Neoadjuvant Treatment of Soft Tissue SarcomaStatus unknownNCT04765228Phase 2
- A Bioequivalence Study of Doxorubicin Hydrochloride Liposome InjectionCompletedNCT04460820Not applicable
- Evaluation of the Sensitivity to Different Chemotherapy Regimens in Platinum-Partial Sensitive Recurrent Ovarian CancerStatus unknownNCT04337632Phase 3
- DCV in the Treatment of Recurrence and Refractory Childhood Solid TumorsStatus unknownNCT04213612Phase 1
- ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBCActive, not recruitingNCT04172259Phase 2